Novo Nordisk Announces 25% Weight Loss in Women with New Drug

• Novo Nordisk announced promising results from a Phase 3 clinical trial of its next-generation obesity drug, CagriSema.
• The trial showed a 25% weight loss in women using CagriSema.
• CagriSema is being positioned as an improvement over Novo Nordisk's existing GLP-1 obesity injection, Wegovy.
• The company, which has struggled with competition and other challenges, hopes the new drug will help turn around its stock performance.
• The results were released on Tuesday and were reported by multiple financial news outlets.